This study evaluated the safety of anti-diabetic drugs in the risk of fractures based on available data from clinical trials. The data showed differences in associations between the use of anti-diabetic drugs and fracture risk.

This study evaluated the effectiveness of insulin glargine 100U/ml (iGlar; Lantus) and lixisenatide (Lixi; Lyxumia) combined (iGlarLixi; Soliqua) compared with each of the two drugs alone in patients with type 2 diabetes (T2D) that was uncontrolled with 2 anti-diabetic oral drugs. The data showed that iGlarLixi resulted in better glucose control compared to iGlar or Lixi, and did not cause abnormally low blood glucose (hypoglycemia).

This study compared the effectiveness and safety of tirzepatide to insulin degludec (Tresiba) in patients with uncontrolled type 2 diabetes (T2D). The data showed that tirzepatide produced better blood glucose control and body weight improvements with reduced risk of hypoglycemia, compared to degludec in these patients.

This study investigated the change in central retinal thickness (CRT) by optical coherence tomography (OCT) in patients with type 2 diabetes (T2D) after 12 weeks of treatment with dapagliflozin (Farxiga) or glibenclamide (Diabeta). The authors concluded that CRT may improve with short-term use of dapagliflozin compared with glibenclamide treatment.

This study looked at the effect of canagliflozin (Invokana) on hospitalization occurrence in patients with type 2 diabetes (T2D). It found that patients treated with canagliflozin were less likely to be admitted to the hospital than patients treated with placebo. 

This study looked at the impact of carotenoids to protect against the development of diabetic retinopathy (DR; eye disease). It found that daily carotenoid supplementation may improve the health of the retina and improve subtle changes in vision caused by DR.

This review looked at whether a vegan diet can improve type 2 diabetes (T2D). It found that a vegan diet can lower glucose (sugar) levels for people with T2D.

This study looked at tirzepatide, a new treatment for type 2 diabetes, compared to semaglutide (Ozempic).  It found that, depending on the dose, tirzepatide was similarly or more effective at controlling blood glucose than semaglutide. 

This study evaluated whether liraglutide (Victoza) improves diabetic control in patients with difficult to control type 2 diabetes (T2D) and if there were certain factors that influence the effects of liraglutide. It found that patients responded equally well to liraglutide regardless of body mass index (BMI; a measurement of weight in relation to height), diabetes duration, and other factors.

This study looked at the safety and effectiveness of tirzepatide (LY-3298176) in patients with type 2 diabetes (T2D) inadequately controlled by diet and exercise alone. It found that compared to placebo, tirzepatide improved diabetes control and weight in these patients.